EUVIMEDEUVIMED entdecken
Crossref

Formononetin Derivative for Osteoporosis by Simultaneous Regulating Osteoblast and Osteoclast

Xiao-Jun Yan, Zhao-Jie Wang iD, Huan Wang, Mei-Zhen Wei, Yi-Chi Chen, Yun-Li Zhao iD, Xiao-Dong Luo iD

Journal of Natural Products · 23.08.2024 · 87 (8) · 2004-2013

DOI: 10.1021/acs.jnatprod.4c00437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Natural Products, online erschienen am 21.07.2024. Verfasst von Xiao-Jun Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Provi…. Hauptthemen laut MEDLINE: Isoflavones, Osteoblasts, Osteoporosis, Osteoclasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Major Science and Technology Projects in Yunnan Province, High-level Talent Promotion and Training Project of Kunming, Yunnan Characteristic Plant Screening and Research and Development Service CXO Platform.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seven new formononetin derivatives (1-7) were designed and prepared from formononetin (phase II phytoestrogen). The derivatives 9-butyl-3-(4-methoxyphenyl)-9,10-dihydro-4H,8H-chromeno[8,7-e][1,3]oxazin-4-one (2) and 9-(furan-3-ylmethyl)-3-(4-methoxyphenyl)-9,10-dihydro-4H,8H-chromeno[8,7-e][1,3]oxazin-4-one (7) promoted significant osteoblast formation by modulating the BMP/Smad pathway. Compound 7 exhibited potent antiosteoclastogenesis activity in RANKL-induced RAW264.7 cells and ovariectomy (OVX)-induced osteoporosis in mice by regulation of the RANK/RANKL/OPG pathway. Compound 7 regulated osteoblast and osteoclast simultaneously and showed better effect than the well-known drug ipriflavone in vivo, suggesting 7 as a patented antiosteoporosis candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoflavonesOsteoblastsOsteoporosisOsteoclastsRANK LigandAnimalsMiceRAW 264.7 CellsFemaleMolecular StructureOvariectomyOsteoprotegerin

Substanzen

IsoflavonesformononetinRANK LigandipriflavoneOsteoprotegerin

Autor:innen und Institutionen

  • Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, School of Pharmacy, Yu…
  • State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, P. R. China.

ORCID-Profile: Zhao-Jie Wang, Yun-Li Zhao, Xiao-Dong Luo

Förderung

  • Major Science and Technology Projects in Yunnan Province
  • High-level Talent Promotion and Training Project of Kunming
  • Yunnan Characteristic Plant Screening and Research and Development Service CXO Platform
  • Yunnan Provincial Science and Technology Department

Zitieren

APA

Yan, X. J., Wang, Z. J., Wang, H., Wei, M. Z., Chen, Y. C., Zhao, Y. L., & Luo, X. D. (2024). Formononetin Derivative for Osteoporosis by Simultaneous Regulating Osteoblast and Osteoclast. Journal of Natural Products, 87(8), 2004-2013. https://doi.org/10.1021/acs.jnatprod.4c00437

Vancouver

Yan XJ, Wang ZJ, Wang H, Wei MZ, Chen YC, Zhao YL, et al. Formononetin Derivative for Osteoporosis by Simultaneous Regulating Osteoblast and Osteoclast. Journal of Natural Products. 2024;87(8):2004-2013. doi:10.1021/acs.jnatprod.4c00437

BibTeX
@article{Yan2024,
  author = {Yan, Xiao-Jun and Wang, Zhao-Jie and Wang, Huan and Wei, Mei-Zhen and Chen, Yi-Chi and Zhao, Yun-Li and Luo, Xiao-Dong},
  title = {Formononetin Derivative for Osteoporosis by Simultaneous Regulating Osteoblast and Osteoclast},
  journal = {Journal of Natural Products},
  year = {2024},
  volume = {87},
  number = {8},
  pages = {2004--2013},
  doi = {10.1021/acs.jnatprod.4c00437}
}
Kostenlos starten →